Slawomir Wozniak1, Katarzyna Nowinska2, Mariusz Chabowski3,4, Piotr Dziegiel5. 1. Division of Anatomy, Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw, Poland. 2. Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw, Poland; katarzyna.nowinska@umw.edu.pl. 3. 4th Military Surgical Clinic in Wroclaw, Wroclaw, Poland. 4. Division of Anesthesiologic and Surgical Nursing, Department of Nursing and Obstetrics, Faculty of Health Science, Wroclaw Medical University, Wroclaw, Poland. 5. Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw, Poland.
Abstract
BACKGROUND/AIM: The role of irisin, the extracellular part of fibronectin type III domain containing 5 (FNDC5), in colorectal cancer (CRC) is unclear. The aim of this study was to investigate immunohistochemical (IHC) expression level of irisin and correlations with clinicopathological factors in patients with CRC. MATERIALS AND METHODS: We collected 222 archived CRC samples and 26 control samples from autopsies conducted at the Department of Forensic Medicine. They were used to perform IHC reactions detecting irisin, Ki-67, minichromosome maintenance protein complex component 3 (MCM3), and urine diphosphate-galactose ceramide galactosyltransferase (UGT3) expression. The correlations with Ki-67, MCM3, and UGT3 were analyzed. Irisin expression was also evaluated in cancer cell lines by immunofluorescence reaction and western blot. RESULTS: Irisin expression was higher in cancer cells compared to the control tissues (p<0.0001). Irisin expression was significantly higher in stage I than in stage III (p=0.013) and IV CRC (p=0.05). CONCLUSION: The correlation between higher expression of irisin and cancer stages indicates its potential usefulness as a marker in CRC.
BACKGROUND/AIM: The role of irisin, the extracellular part of fibronectin type III domain containing 5 (FNDC5), in colorectal cancer (CRC) is unclear. The aim of this study was to investigate immunohistochemical (IHC) expression level of irisin and correlations with clinicopathological factors in patients with CRC. MATERIALS AND METHODS: We collected 222 archived CRC samples and 26 control samples from autopsies conducted at the Department of Forensic Medicine. They were used to perform IHC reactions detecting irisin, Ki-67, minichromosome maintenance protein complex component 3 (MCM3), and urine diphosphate-galactose ceramide galactosyltransferase (UGT3) expression. The correlations with Ki-67, MCM3, and UGT3 were analyzed. Irisin expression was also evaluated in cancer cell lines by immunofluorescence reaction and western blot. RESULTS: Irisin expression was higher in cancer cells compared to the control tissues (p<0.0001). Irisin expression was significantly higher in stage I than in stage III (p=0.013) and IV CRC (p=0.05). CONCLUSION: The correlation between higher expression of irisin and cancer stages indicates its potential usefulness as a marker in CRC.
Authors: Hyeonwoo Kim; Christiane D Wrann; Mark Jedrychowski; Sara Vidoni; Yukiko Kitase; Kenichi Nagano; Chenhe Zhou; Joshua Chou; Virginia-Jeni A Parkman; Scott J Novick; Timothy S Strutzenberg; Bruce D Pascal; Phuong T Le; Daniel J Brooks; Alexander M Roche; Kaitlyn K Gerber; Laura Mattheis; Wenjing Chen; Hua Tu; Mary L Bouxsein; Patrick R Griffin; Roland Baron; Clifford J Rosen; Lynda F Bonewald; Bruce M Spiegelman Journal: Cell Date: 2018-12-13 Impact factor: 41.582
Authors: Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2017-03-01 Impact factor: 508.702
Authors: S Aydin; T Kuloglu; M R Ozercan; S Albayrak; S Aydin; U Bakal; M Yilmaz; M Kalayci; M Yardim; M Sarac; A Kazez; H Kocdor; B Kanat; İ H Ozercan; M Gonen; M Bilgen; F Balgetir Journal: Biotech Histochem Date: 2016-03-10 Impact factor: 1.718
Authors: Paul C Mayor; Kevin H Eng; Kelly L Singel; Scott I Abrams; Kunle Odunsi; Kirsten B Moysich; Ramsay Fuleihan; Elizabeth Garabedian; Patricia Lugar; Hans D Ochs; Francisco A Bonilla; Rebecca H Buckley; Kathleen E Sullivan; Zuhair K Ballas; Charlotte Cunningham-Rundles; Brahm H Segal Journal: J Allergy Clin Immunol Date: 2017-06-09 Impact factor: 10.793
Authors: Brian O'Sullivan; James Brierley; David Byrd; Fred Bosman; Sean Kehoe; Carol Kossary; Marion Piñeros; Elizabeth Van Eycken; Hannah K Weir; Mary Gospodarowicz Journal: Lancet Oncol Date: 2017-07 Impact factor: 41.316
Authors: Jun Wu; Pontus Boström; Lauren M Sparks; Li Ye; Jang Hyun Choi; An-Hoa Giang; Melin Khandekar; Kirsi A Virtanen; Pirjo Nuutila; Gert Schaart; Kexin Huang; Hua Tu; Wouter D van Marken Lichtenbelt; Joris Hoeks; Sven Enerbäck; Patrick Schrauwen; Bruce M Spiegelman Journal: Cell Date: 2012-07-12 Impact factor: 41.582
Authors: Pontus Boström; Jun Wu; Mark P Jedrychowski; Anisha Korde; Li Ye; James C Lo; Kyle A Rasbach; Elisabeth Almer Boström; Jang Hyun Choi; Jonathan Z Long; Shingo Kajimura; Maria Cristina Zingaretti; Birgitte F Vind; Hua Tu; Saverio Cinti; Kurt Højlund; Steven P Gygi; Bruce M Spiegelman Journal: Nature Date: 2012-01-11 Impact factor: 49.962